JP2016540050A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540050A5
JP2016540050A5 JP2016555933A JP2016555933A JP2016540050A5 JP 2016540050 A5 JP2016540050 A5 JP 2016540050A5 JP 2016555933 A JP2016555933 A JP 2016555933A JP 2016555933 A JP2016555933 A JP 2016555933A JP 2016540050 A5 JP2016540050 A5 JP 2016540050A5
Authority
JP
Japan
Prior art keywords
amino acid
moiety
seq
acid residues
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555933A
Other languages
English (en)
Japanese (ja)
Other versions
JP6792452B2 (ja
JP2016540050A (ja
Filing date
Publication date
Priority claimed from GBGB1321242.8A external-priority patent/GB201321242D0/en
Application filed filed Critical
Publication of JP2016540050A publication Critical patent/JP2016540050A/ja
Publication of JP2016540050A5 publication Critical patent/JP2016540050A5/ja
Application granted granted Critical
Publication of JP6792452B2 publication Critical patent/JP6792452B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555933A 2013-12-02 2014-12-02 免疫原性化合物 Expired - Fee Related JP6792452B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1321242.8A GB201321242D0 (en) 2013-12-02 2013-12-02 Immunogenic compound
GB1321242.8 2013-12-02
PCT/GB2014/053577 WO2015082905A1 (en) 2013-12-02 2014-12-02 Immunogenic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020185572A Division JP7095053B2 (ja) 2013-12-02 2020-11-06 免疫原性化合物

Publications (3)

Publication Number Publication Date
JP2016540050A JP2016540050A (ja) 2016-12-22
JP2016540050A5 true JP2016540050A5 (enExample) 2018-01-25
JP6792452B2 JP6792452B2 (ja) 2020-11-25

Family

ID=49979653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016555933A Expired - Fee Related JP6792452B2 (ja) 2013-12-02 2014-12-02 免疫原性化合物
JP2020185572A Expired - Fee Related JP7095053B2 (ja) 2013-12-02 2020-11-06 免疫原性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020185572A Expired - Fee Related JP7095053B2 (ja) 2013-12-02 2020-11-06 免疫原性化合物

Country Status (10)

Country Link
US (4) US9962453B2 (enExample)
EP (1) EP3077052A1 (enExample)
JP (2) JP6792452B2 (enExample)
KR (1) KR102356869B1 (enExample)
CN (1) CN105873638A (enExample)
BR (1) BR112016012528A2 (enExample)
CA (1) CA2931933A1 (enExample)
EA (1) EA201691146A1 (enExample)
GB (1) GB201321242D0 (enExample)
WO (1) WO2015082905A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2018175854A1 (en) * 2017-03-23 2018-09-27 The Children's Medical Center Corporation Methods and compositions relating to adjuvants
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ， インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
WO2020010394A1 (en) 2018-07-10 2020-01-16 Seqirus Pty Ltd Removal of agglomerates
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CA3135913A1 (en) * 2019-04-01 2020-10-08 Altimmune Uk Ltd Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines
TWI894573B (zh) * 2022-06-09 2025-08-21 中央研究院 Nod1調節劑及其用途
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
KR102784104B1 (ko) * 2024-04-04 2025-03-24 대한민국(방위사업청장) 이미퀴모드 및 Nod2 수용체 자극 성분 또는 박테리아를 포함하는 면역 어쥬번트

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
FR2744123B1 (fr) * 1996-01-26 1998-04-17 Carelli Claude Marcel Henri Molecules biologiquement actives plus particulierement peptidiques ayant un effet potentialisateur de l'activite biologique de l'hormone de croissance
IL161786A0 (en) 2001-11-29 2005-11-20 3M Innovative Properties Co Pharmaceutical formulations comprising an immune
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
CA2605808A1 (en) 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
PT2341933T (pt) 2008-10-24 2018-02-13 Glaxosmithkline Biologicals Sa Derivados de imidazoquinolina lipidados
EP2387421A1 (en) * 2009-01-14 2011-11-23 SKU Asset Management GmbH Compounds comprising n-formyl-methionine residues and tumor-targeting peptides
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
WO2011103465A2 (en) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
WO2012113413A1 (en) * 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound

Similar Documents

Publication Publication Date Title
JP7095053B2 (ja) 免疫原性化合物
CN103402539B (zh) 一种用于产生对抗病原体的持久免疫和保护的合成免疫原
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
Fifis et al. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice
KR102239207B1 (ko) 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
CN110279853A (zh) 包含聚合载体货物复合物和至少一种蛋白或肽抗原的药物组合物
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
Keijzer et al. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion
JP2015530413A (ja) 改良されたワクチン組成物および使用方法
WO2019213555A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
US20090214598A1 (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
JP7561182B2 (ja) ペプチドがロードされたキャリアシステムおよびその使用
Tohumeken et al. A modular antigen presenting peptide/oligonucleotide nanostructure platform for inducing potent immune response
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
US20230109142A1 (en) Corona virus vaccine
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell
HK1130687A (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease